Article Text

Download PDFPDF

THU0221 Downregulated expression of MIR200B-5P in minor salivary glands (MSG) of patients with sjÖgren's syndrome (SS) associated lymphoma
  1. EK Kapsogeorgou,
  2. A Papageorgiou,
  3. M Voulgarelis,
  4. AG Tzioufas
  1. Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, ATHENS, Greece


Background The miRNAs of the miR-200 family are critical regulators of oncogene and tumor suppressor genes. Preliminary data from a limited number of patients with SS-associated lymphoma suggested that the expression of miR200b-5p in MSGs may be downregulated in lymphoma.

Objectives To validate whether low miR200b-5p MSG-levels are associated with SS-related lymphomas and if they are deregulated before lymphoma development, suggesting a possible prognostic value.

Methods miR200b-5p expression was analyzed by quantitative real-time PCR in total RNA from MSG tissues obtained from 77 SS patients and 9 patients with non-SS sialadenitis associated with sarcoidosis, HCV infection (4 each) or HBV (1 that was also diagnosed with MALT lymphoma). with chronic sialadenitis associated with sarcoidosis, HCV (4-each) or HBV infection (1 who was also diagnosed with MALT-lymphoma). SS-patients included 28 that did not develop lymphoma during follow-up (without lymphoma; median follow-up time since biopsy performance, range: 6yrs, 1–12.75yrs), 18 that developed lymphoma in the future (prelymphoma; median follow-up time till lymphoma diagnosis, range: 3.59yrs, 0.42–8.5yrs, 15-MALT, 2-NMZL, 1-DLCBL) and 32 with SS-associated lymphoma at the time of biopsy (lymphoma; 25-MALT, 2-NMZL, 2-DLCBL, 1-BALT, 1-LP and 1-SLL). In 15 cases, we had sequential MSG-samples from prelymphoma patients who transitioned to lymphoma (12-MALT, 2-NMZL, 1-DLCBL).

Results Tukey's multiple comparison revealed that miR200b-5p levels were significantly down-regulated in MSG tissues of prelymphoma and lymphoma SS-patients (mean relative expression±SE: 0.37±0.10 and 0.26±0.06, respectively) compared to SS-patients without lymphoma (0.67±0.07; p≤0.05 and p≤0.0001 for pre- and lymphoma, respectively) or non-SS sialadenitis (0.85±0.28, p≤0.05 and p≤0.01, respectively). Interestingly, low miR200b-5p levels were detected in HBV patient that had MALT lymphoma (0.17). The expression of miR200b-5p was not found to differ between patients with SS without lymphoma and non-SS sialadenitis, or SS-associated pre-lymphoma and lymphoma. The analysis of the 15 cases of SS patients that had sequential samples before and on lymphoma diagnosis revealed that miR200b-5p levels do not significantly change over transition to lymphoma. The miR200b-5p expression levels were negatively correlated with the biopsy focus score (r:-0.6550, p<0.0001), whereas they were not associated with the site or the number of involved sites, the type or the stage of lymphoma.

Conclusions The significantly low levels of miR200b-5p in MSG tissues of patients with SS-associated prelymphomas and lymphomas suggest that miR200b-5p deregulation is implicated in SS-lymphomagenesis. The downregulation of miR200b-5p in prelymphoma samples and the lack of change over transition to lymphoma suggest that it can serve as a prognostic marker for future lymphoma development. The prognostic value of miR200b-5p in SS-associated lymphomas, the expressing cell types and affected molecular pathways are under investigation.

Acknowledgements Funded by the Hellenic College of Rheumatology

Disclosure of Interest None declared

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.